It is positive news for Novo, says analyst Søren Løntoft Hansen, Sydbank, about last week’s publication of data from a phase III study with company’s drug against haemophilia B, N9-GP.
“Compared with haemophilia A, however, haemophilia B is rarer, meaning the population is also smaller. Moreover, the market is conservative and a switch from one drug to another is less common than seen elsewhere,” he explains to Medwatch and adds:
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app